MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 ZUG, Switzerland, March 4, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that 24-week data from its Phase 2 MIRA trial with the Nanobody sonelokimab in moderate to severe hidradenitis suppurativa (HS), will be presented in a late breaking oral session on March 10 at 14:00 PST at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 8-12, in San Diego, California.

MoonLake Immunotherapeutics将在2024年3月4日于瑞士祖格举行的AAD 2024年年会上展示Nanobody®sonelokimab在化脓性汗腺炎中作为晚期破坏者的MIRA试验数据–MoonLake Immunotherapeutics（“MoonLake”；Nasdaq:MLTX），这是一家临床阶段的生物技术公司，专注于为炎症性疾病创造新的治疗方法，今天宣布，使用纳米抗体sonelokimab治疗中度至重度化脓性汗腺炎（HS）的2期MIRA试验的24周数据将于3月10日下午14:00 PST在2024年美国皮肤病学会（AAD）年会上于3月8日至12日在加利福尼亚州圣地亚哥举行。

Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake commented: “We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation. Hidradenitis suppurativa is a severely debilitating chronic skin condition and the data will showcase the therapeutic effect of maintenance treatment with our Nanobody® sonelokimab.” The oral presentation titled “Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial” will be presented by Professor Brian Kirby MD, FRCPI, Department of Dermatology, St.

克里斯蒂安·赖希，医学博士，博士，MoonLake首席科学官评论道：“我们很高兴我们的2期MIRA试验的24周数据被美国皮肤病学会选为口服迟发性报告。化脓性汗腺炎是一种严重衰弱的慢性皮肤病，数据将展示我们的Nanobody®sonelokimab维持治疗的治疗效果。”名为“IL-17A和IL-17F抑制性纳米抗体sonelokimab在中度至重度化脓性汗腺炎（HS）患者中的疗效和安全性：第2期MIRA试验的第24周结果”的口头报告将由圣路易斯皮肤病学系FRCPI教授Brian Kirby MD介绍。

Vincent’s University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland. The presentation will be held on Sunday 10 March at 14:00 PST / 17:00 EST / 23:00 CET during the late breaking research session 2 (S050) in room 20B. Key members of the MoonLake team, including the executive leadership team, will attend AAD.

爱尔兰都柏林都柏林大学学院文森特大学医院和查尔斯皮肤病研究所。演讲将于3月10日（星期日）下午14:00（太平洋标准时间）/17:00（美国东部标准时间）/23:00（欧洲中部标准时间）在20B室举行的第二次迟发研究会议（S050）期间举行。月亮湖团队的关键成员，包括执行领导团队，将参加AAD。

In June 2023, MoonLake ann.

2023年6月，MoonLake ann。